Publicacións (217) Publicacións de JOSE LUIS LABANDEIRA GARCIA Ver datos de investigación referenciados.

2024

  1. Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Hypothalamic free fatty acid receptor-1 regulates whole-body energy balance

    Molecular Metabolism, Vol. 79

  3. Inflammatory bowel disease induces pathological α-synuclein aggregation in the human gut and brain

    Neuropathology and Applied Neurobiology, Vol. 50, Núm. 1

  4. Ionizable nanoemulsions for RNA delivery into the central nervous system – importance of diffusivity

    Journal of Controlled Release, Vol. 372, pp. 295-303

  5. Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models

    Stem Cell Research and Therapy, Vol. 15, Núm. 1

  6. The role of the brain renin-angiotensin system in Parkinson´s disease

    Translational Neurodegeneration, Vol. 13, Núm. 1

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  3. Astrocytic insulin receptor controls circadian behavior via dopamine signaling in a sexually dimorphic manner

    Nature Communications, Vol. 14, Núm. 1

  4. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  5. Combined cell-based therapy strategies for the treatment of Parkinson's disease: Focus on mesenchymal stromal cells

    Neural Regeneration Research, Vol. 18, Núm. 3, pp. 478-484

  6. Extracellular Vesicles and Their Renin–Angiotensin Cargo as a Link between Metabolic Syndrome and Parkinson’s Disease

    Antioxidants, Vol. 12, Núm. 12

  7. Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia

    Antioxidants, Vol. 12, Núm. 7

  8. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

  9. Small extracellular vesicle targeting of hypothalamic AMPKα1 promotes weight loss in leptin receptor deficient mice

    Metabolism: clinical and experimental, Vol. 139, pp. 155350

  10. The cannabinoid CB1 receptor interacts with the angiotensin AT2 receptor. Overexpression of AT2-CB1 receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats

    Experimental Neurology, Vol. 362

2022

  1. Angiotensin System Autoantibodies Correlate With Routine Prognostic Indicators for COVID-19 Severity

    Frontiers in Medicine, Vol. 9

  2. Angiotensin Type-1 Receptor Inhibition Reduces NLRP3 Inflammasome Upregulation Induced by Aging and Neurodegeneration in the Substantia Nigra of Male Rodents and Primary Mesencephalic Cultures

    Antioxidants, Vol. 11, Núm. 2

  3. Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease

    npj Parkinson's Disease, Vol. 8, Núm. 1

  4. Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment

    Biomedicines, Vol. 10, Núm. 2